AbbVie Inc. (ABBV) vs Eli Lilly and Company (LLY)
See how AbbVie Inc. and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.
$256.42
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
View Full Page$1,156.73
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full PageKey Metrics Comparison
AbbVie Inc.ABBV
Market Cap$453.124B
Price$256.42
24h Change+0.37%
24h Volume$4.24M
Employees57,000
Shares Outstanding1,768,169,012
Eli Lilly and CompanyLLY
Market Cap$1.032T
Price$1,156.73
24h Change-1.52%
24h Volume$3.03M
Employees50,000
Shares Outstanding944,818,881
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
ABBV
30.5%LLY
69.5%Volume Share
Share of combined 24h volume
ABBV
58.3%LLY
41.7%24h Performance
Price change over last 24 hours
ABBV
0.37%LLY
-1.52%Price Comparison
AbbVie Inc.
Eli Lilly and Company